Zejing Pharmaceuticals (688266.SH): Clinical data for ZG006 and ZG005 will be released at the 2025 European Society for Medical Oncology (ESMO) Annual Meeting.

Zejing Pharmaceutical (688266.SH) announced that the clinical research data and latest developments of the company's independently developed new drugs Alveltamig (code: ZG006) and Nilvanstomig (code: ZG005) will be released at the European Society for Medical Oncology (ESMO) annual meeting from October 17 to 21, 2025. Based on the data of ZG006 monotherapy in patients with advanced SCLC and NEC, it further demonstrates that ZG006 monotherapy has outstanding and durable antitumor efficacy in patients who have failed standard treatments for SCLC or NEC, and has good tolerance and safety. In patients with advanced neuroendocrine tumors, the combination of ZG005 with chemotherapy is well tolerated and safe, showing good efficacy, supporting further clinical research.